7/24/13

Future Of Clinical Trials In India - Food, Drugs, Healthcare, Life Sciences - India

W e us e c ook ies t o give y ou t he bes t online ex perienc e. B y us ing our webs it e y ou agree t o our us e of c ook ies in ac c ordanc e wit h our c ook ie polic y .
Learn more here .
Close Me

Home > India > Food, Drugs, Healthcare, Life Sciences

India: Future Of Clinical Trials In India

Last Updated: 28 June 2013
Article by Priyesh Sharma, Vaish Associates Advocates Delhi, India
Vaish Associates Advocates
0

Introduction: "Clinical Trials" and debates associated with it have been in headlines since past few months pursuant to the strict
view taken by the apex court on the matter. The number of deaths in India resulting from clinical trials has increased to an
unendurable figure of 2,868 during the period 2005-20121. If on the one hand this figure relating to number of deaths resulting from
clinical trials is fearful, on the other hand the decline in the number of clinical trials and approval given for conducting such trials in
last few months is equally shocking. Till April 2013, only 12 (twelve) clinical trials have been approved by the authority as compared
to almost a three digit figure in last year2. This certainly raises a concern for the future of clinical trials in India- country which once
was perceived as a fertile place for growth of clinical trials by most of the multi-national corporations. Currently estimated at USD
500 million, India's clinical research market was projected to more than double and cross USD one billion mark by 2016 driven by
favorable factors like diverse and accessible population, availability of low cost and effective resources3.
The controversies relating to clinical trials are not something which can be decided in black and white. Rather it's an interface of
elements like law, ethics, scientific development, human rights and social good. As these scientific tests and trials involve
application of advanced technologies, there is a need for well framed rules and laws for the conduct of these tests and trials.
Certainly it's not easy to set an order of priority or precedence among these elements.
This Article is an attempt to analyze the current controversy revolving around the clinical trials in India and to come out with
feasible suggestions to ensure the ethical conduct of such clinical trials without undermining the need of scientific research and
development and its benefits to society. However before proceeding further, it is necessary to understand in nutshell what does
"clinical trial" actually means and how are they regulated in India.
What are "Clinical Trials"? Clinical trials in layman's language mean any investigation on human subjects carried out by
pharmaceutical experts in order to discover or verify the clinical and pharmacological effects of any investigational medicinal
product(s) and/or to identify any adverse reactions of such medicinal products(s) and/or to study such investigational medicinal
product(s) with the object of ascertaining its safety and/or efficacy. Like any standard scientific and research activity, clinical trials
are carried out with a definite aim through well- defined procedure and under closed conditions.
Applicable laws and regulatory framework: Clinical trials, in addition to national laws, are governed by well established
guidelines and directives at international level like EU regulations and directives, ICH- Good Clinical Practices (GCP) guidelines,
recommendations of World Medical Association Declaration of Helsinki, Guidelines for Good Pharmacoepidemiology Practices
and ICMR guidelines. These guidelines, recommendations and opinions are considered as "soft law" and are not legally binding
but play an important role in regulating these clinical trials. Most of the multi -national corporations carrying out clinical trials
worldwide voluntarily and as a good practice follow these guidelines and recommendations. These guidelines and directives
primarily aim at protecting the subject from taking undue risk in participating in a clinical trial; enforce both voluntary consent to
research and the continual assessment of risk and benefit. In India, Central Drugs Standard Control Organization (CDSCO)
(headed by Director Control General of India) is the primary authority and "Drugs and Cosmetics Act, 1940" (along with the rules
framed there under) is the principal legislation for the regulation of clinical trials. Schedule Y of the Drugs and Cosmetics Rules,
1945 ("Rules") provides for the detailed conditions, and compliances relating to clinical trials in India.
Recent amendment to Schedule Y of Drugs and Cosmetics Rules, 1945: Recently on 30th January 20134, Government of
India came out with certain amendments to Schedule Y of the Rules with a view to tighten the norms relating to the conduct of
www.mondaq.com/404.asp?404;http://www.mondaq.com:80/india/x/247668/food+drugs+law/Future+Of+Clinical+Trials+In+India&login=true

1/5

7/24/13

Future Of Clinical Trials In India - Food, Drugs, Healthcare, Life Sciences - India

clinical trials especially in terms of taking informed consents from the trial subjects and providing them or their legal representatives
(as the case may be) compensation in case of any trial related injury or death. The amendment has imposed complete and ultimate
liability on the sponsor of the clinical trial to reimburse any cost incurred by the trial subjects for the medical treatment of "any injury"
suffered by the trial subjects as well as financial compensation for such injury or death. Further in case the sponsor fails to provide
the proper medical treatment and/ or the financial compensation as per the orders of the licensing authority to the trial subjects (or
their representatives as the case may be), then the authority may cancel or suspend the license of the sponsor to carry out the
clinical trials and may even debar it from carrying any clinical trial in future in India. The amendment also mandates GCP
compliance and adverse event reporting. The amendment has certainly acted as a deterrent on the multi-national corporations and
is a negative catalytic agent to the prospects of clinical trials in India.
Ins and outs of the amendment: The aforesaid amendments to Schedule Y of the Rules came as a response to demands from
the apex court, which were outraged by the lack of supervision and regulation of these clinical trials in India. As per the law existing
prior to the said amendment, sponsors of the clinical trials were required to pay compensation "for deaths that results from clinical
trials". Further there was no prescribed formula or minimum amount for determining such compensation and the time lines for
making such payments by the sponsor in the Rules. Consequently only 45 out of 2,868 were reported to receive the compensation
by the sponsors in last 7 years5. Additionally, there were no minimum clinical standards for trials prescribed under the law, for
instance the requirement of registrations of the entities/ clinical research organizations conducting such trials, defined conditions
and ethical standards to be complied with while conducting such trials.
After instances of unethical trials and unpaid compensations reached the courts and CDSCO early this year, CDSCO as a
measure to bring about a planned change to the law relating to clinical trials in India decided to bring on table the amendments to
schedule Y of Rules.
Also as a response to the public interest litigation(s) filed by few NGOs working for the human rights of the vulnerable sections, the
apex court has acknowledged the lack of proper standard of care adopted by the clinical research organizations, lacunas in the
existing legal framework and has shown serious concerns over the use of Indian subjects as "guinea pigs" in the conduct of clinical
trials by the multi- national giants. This further triggered the CDSCO and Ministry of Health and Welfare to tighten the norms relating
to the conduct of clinical trials and also the approval mechanism for such clinical trials.
While the human rights activists and NGOs are supporting the amendments to Schedule Y of the Rules, the pharmaceutical industry,
sponsor pharmaceutical companies and clinical research organizations are certainly not unanimous with respect to supporting
these amendments. As a result of stricter compliances and uncertain approval process, the number of clinical trials coming to India
has decreased significantly in the recent past. One of the reasons for the decrease is due to the unpredictable nature of the
regulatory timelines for clinical trial approval and the unreasonable demands of the authorities like protocol amendments, site
selection etc. which in turn further increases the unpredictability and timelines associated with regulatory approvals. There are
some who argue that this will just increase the cost of doing clinical trial in India, eventually pricing out local drug manufacturers and
making India affordable only for multinational corporations. However it cannot be overlooked that as a result of aforesaid
amendments and uncertain approval mechanism, the multi-national corporations would prefer other locations for carrying out the
clinical trials like China, South Korea and Russia which provide a comparatively flexible and less strict regulatory atmosphere for
carrying out clinical trials.
Not only the sponsors are affected by the change in regulatory scenario but also the doctors and investigators involved in the clinical
trials are facing the consequences of these amendments. For example, as per the amended Schedule Y of the Rules, the
investigators have an obligation to report any serious adverse effect of the drug under investigation within 24 hours of the
"occurrence of such effect". Also sponsor has a responsibility to forward such reports within 10 days of the occurrence of such
serious adverse event. However it is not practically possible to do so in most of the cases. Since such effects are not always
physical or visible, it can be reported by the investigators only once they themselves became aware about the adverse effects of the
drug through the subject or its representatives. Reporting of adverse effects and serious adverse effects are important since the
same are directly related to the clinical trial injury and payment of financial compensation by the sponsors and hence the ambiguity
in the amended language needs to be clarified by the authorities soon to avoid any ambiguity.
Striking out a balance between need for strict regulatory regime and the growth of clinical trials in India: Clinical trials not
only contribute to the scientific research and development but also ensure better patient care than normal clinical practice and in
long run is a boon for the society as it eventually leads to the development of new generic drugs and medicines. It is unfortunate that
India is losing out the opportunity to other nations because of the uncertainties in the regulatory framework and approval
mechanism.
Without undermining the need of amending the existing regulations relating to the clinical trials thereby making the clinical trials
safer and preventing the exploitation of vulnerable subjects participating in such trials, it is necessary to appreciate that we as a
www.mondaq.com/404.asp?404;http://www.mondaq.com:80/india/x/247668/food+drugs+law/Future+Of+Clinical+Trials+In+India&login=true

2/5

7/24/13

Future Of Clinical Trials In India - Food, Drugs, Healthcare, Life Sciences - India

developing economy with the conditions so suitable for clinical trials like diverse population, cost effective facilities and resources,
presence of reputed pharmaceutical companies including subsidiaries of such multinational corporations willing to act as a sponsor
and trained investigators, should not restrict the growth of clinical trials and instead try to promote a strong culture of research and
development in the health sector in India.
No company or institution desires to be get publicized negatively or defend itself over ethical issues like violation of human rights or
unethical treatment of patients, for any reason whatsoever. In today's diverse and competitive business environment, one must
acknowledge that law often embodies ethical principles, but law and ethics are far from co-extensive. Regulators have to and
should take into account other elements like social utility, economic growth etc. also while framing laws and hence it is not
necessary that law would always prohibit something which is considered as unethical and the vice versa holds good.
There is a strong requirement for liberalizing the regulatory environment in favor of the sponsors conducting such trials and at the
same time balancing the interest of the subjects involved in such trials. Further the approval mechanism needs to be more
transparent and time efficient. Concerns raised by the human rights activist and NGOs are genuine, but rejecting or delaying the
approval to the applications for conducting clinical trials is in no way a solution to the problem. Law should be for the "regulation" of
the clinical trials and not for "restricting" the clinical trials. Instead of dismissing clinical trials or delaying the approval process, what
is required is to identify and fix the loopholes in the regulatory framework and implement existing laws effectively to ensure that
clinical trials are conducted with utmost transparency and diligence. Otherwise we would end up losing the prospects of growth of
clinical research activities in India, which would certainly be a huge loss to our health care sector.
Way Forward: Following are some of the changes suggested in the existing law, which can go a long way to strike a balance
between the interest of the subjects and the growth of clinical trials in India:
1. Informed consent: Improvement in the system of obtaining informed consent from the subjects. Audio/ visual techniques of
recording should be used while explaining the subjects about the process, the likely side effects and taking their consent.
Further, subjects should be clearly informed about the past records of such clinical trials and number of adverse
effects/deaths reported due to such clinical trials. Merely poverty and free treatment should not be the basis of engaging
subjects in the clinical trials. Investigators and sponsor should be morally responsible in this regard.
2. Restricting the liability of sponsors: Restricting the liability of the sponsors to the injury or death of the subject which are
resulting directly or sufficiently attributable to the participation of the subjects in the clinical trials. With as many as 2,868
deaths during clinical trials from 2005 to 2012, only 89 have been attributed directly to such trials6. The timelines for payment
of compensation should be liberalized depending upon the case to case basis. A fixed timeline in all type of adverse events
and claims may not serve the purpose. Further the amount of financial compensation (over and above the cost of medical
treatment) should be quantified or objective criteria to determine the same should be ascertained. For example, a terminally ill
patient who chooses to be the subject of a clinical trial need not be given the same compensation as a healthy individual who
has opted to become the subject for clinical trial. It should not be left at the sole discretion of the licensing authority or ethics
committee.
3. Institutionalization and registrations: Independent research and trials should be restricted and only institutionalized clinical
trials to be carried out. It is commonly seen that investigators and doctors at individual level carry out unregulated clinical
research in private clinics and hospitals. This is required to be checked by the authorities. Registration of clinical trials with
Clinical Trials Registry India and registration of clinical research organizations should be mandatory. This is already in place,
however the effective implementation of the same should be ensured.
4. Approval mechanism: Fast and time efficient approval mechanism is required. Objective criteria for accepting or rejecting
the applications, transparency in the entire process and the decisions for rejection or pending applications should be
supported with the appropriate reasons. It is to be noted that the approval time for initiating drug trials in India typically runs
from six to eight months, compared to 28 days in Europe and Canada.7
5. Transparency: Transparency from the side of investigators and institutions is also very important. It is one of the core guiding
principles in the ICMR Ethics Guidelines. Institutions and investigators should be open to public about regarding kind of
investigation, standard of care taken, subjects involved, etc.
6. Inspection and auditing: Officials of the CDSCO or licensing authority carrying out the inspection of the site should be of the
same field with adequate knowledge and expertise on the subject. Also the use of CCTV camera at the trial site to administer
the whole procedure of trial should be implemented. Further, involvement of the experts from the industry and legal field in the
ethics committee and more emphasis on institutionalization of the ethics committee is also necessary. These would help the
ethics committee and regulatory authority to investigate the matter more efficiently.
7. Applicability of stringent laws: Multi-national corporations which are voluntarily following the internationally recognized
guidelines and directives or are governed by laws of other home countries which are materially equivalent strict in terms of
following the good clinical standards and protecting the interest of the subjects, should not be made to comply with more
procedural compliances and practices and should be provided a conducive regulatory atmosphere for coming to India and
carrying out clinical trials.
8. Drugs with serious side effects: It is seen that most of the deaths occurred in the past few years is due to some specific drugs
which were time and again put to investigation and every time resulted in the severe adverse effects. Special care should be
taken in approving the clinical trials of such drugs and only in exceptional cases and depending upon the utility of such drug
the permission should be given.
www.mondaq.com/404.asp?404;http://www.mondaq.com:80/india/x/247668/food+drugs+law/Future+Of+Clinical+Trials+In+India&login=true

3/5

7/24/13

Future Of Clinical Trials In India - Food, Drugs, Healthcare, Life Sciences - India

9. Role of media: Negative publicity of clinical trials and multi- national corporations involved in such trials should be avoided
and discouraged. Media should be responsible in spreading any critical report relating to the clinical trials and same should
be approved by the licensing authority in advance. In past it is seen that out of the 2,868 deaths reported only 89 of them were
taken place due to clinical trials8. Rest were either remotely related to the trial or were in regular course due to the disease of
the subjects. Such negative publicity discourages the sponsor and creates uncertainties in the mind of the subjects. Rather
media should emphasize on spreading awareness about such clinical trials targeting the vulnerable sections who mostly get
involved in trials as subjects.
10. Pending actions from the side of Government: The proposal of Ministry of Health and Family Welfare with respect to forming
a committee comprising of science and regulatory experts that would formulate policy on drug approvals, clinical trials and
drug bans should be implemented promptly. Also the draft bill on Biomedical Research on Human Participants (Promotion
and Regulation) prepared by the Indian Council of Medical Research should be tabled in the parliament on priority basis. It
would be beneficial if the comments and suggestions of the experts from the industry are taken.
11. Clarification: Removing the loopholes in the language of the amended schedule Y (for instance as mentioned above the time
period with respect to the reporting of serious adverse events) and bringing clarity to the same.
The ethical concerns of the clinical trials cannot be removed completely. But the above suggestions, if implemented, can certainly
give bright prospect to the growth of clinical trials and research in the health care sector in India and would help in regaining the lost
confidence of the multi-national corporations interested in carrying out clinical trials in India. At the cost of repetition, I would like to
reiterate: Law should be for the "regulation" of the clinical trials and not for "restricting" the clinical trials!

Footnotes
1 Please see : http://www.business-standard.com/article/pti-stories/only-45-of-2-868-clinical-trial-deaths-compensated-since-2005-113030500403_1.htm l;
last visited on June 21, 2013
2 Please see : http://www.thehindu.com/sci-tech/health/policy-and-issues/post-stringent-norms-clinical-trials-in-india-plummet/article4639976.ece ; last
visited on June 21, 2013
3 Frost & Sullivan report, please see http://www.thehindubusinessline.com/industry-and-economy/clinical-trial-market-to-reach-1-billion-by-2016report/article3877317.ece ., last visited on June 21, 2013
4 Notification GSR 53(E) dated January 30, 2013 For more details please see: http://www.cdsco.nic.in/GSR%2053(E)%20dated%2030.01.2013.pdf , last
visited in June 21, 2013
5 Supra foot note no. 1
6 Supra foot note no. 1
7 Please see http://www.pharmalive.com/india-losing-its-edge-clinical-trials , last visited on June 21, 2013.
8 Supra foot note no. 1

2013, Vaish Associates, Advocates,

All rights reserved with Vaish Associates, Advocates, 10, Hailey Road, Flat No. 5-7, New Delhi-110001, India.
The content of this article is intended to provide a general guide to the subject matter. Specialist professional advice should be
sought about your specific circumstances. The views expressed in this article are solely of the authors of this article.
D o yo u h a ve a Qu e s ti o n o r C o m m e n t?

In te re s te d i n th e n e xt We b i n a r o n th i s To p i c?

Cl i ck h e re t o e m a i l t h e A u t h o r

Cl i ck h e re t o re g i st e r yo u r I n t e re st

Contributor
P riy es h S harma, V ais h
A s s oc iat es A dvoc at es Delhi,
India

Email Firm

More from this Firm

View Website

More from this Author

V ais h A s s oc iat es A dvoc at es

Contact Us | Your Privacy | Feedback

Mondaq Ltd 1994 - 2013

All Rights Reserved

www.mondaq.com/404.asp?404;http://www.mondaq.com:80/india/x/247668/food+drugs+law/Future+Of+Clinical+Trials+In+India&login=true

4/5

7/24/13

Future Of Clinical Trials In India - Food, Drugs, Healthcare, Life Sciences - India

www.mondaq.com/404.asp?404;http://www.mondaq.com:80/india/x/247668/food+drugs+law/Future+Of+Clinical+Trials+In+India&login=true

5/5